Literature DB >> 32132045

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan.

Peter J Hurley1, Nandita Bose2, Gautam Jha3, Michele Gargano2, Nadine Ottoson2, Keith Gorden2, Blaine Rathmann2, Ben Harrison2, Xiaohong Qiu2, Arkadiusz Z Dudek4,3.   

Abstract

BACKGROUND: BTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum is necessary for BTH1677 antitumoral activity. We hypothesized that infusion of immunoglobulin can reinstate responses to BTH1677 in individuals with low ABA levels. PATIENTS AND METHODS: We report two single-patient studies: one in a patient with metastatic colorectal cancer who received BTH1677, combined with tumor targeting antibody cetuximab; and a second in a patient with metastatic neuroendocrine tumor who received BTH1677 combined with immune checkpoint inhibitor pembrolizumab.
RESULTS: The patients had low serum titers of ABA and low innate immune effector functionality induced by BTH1677. Addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoral activity, with long-term disease control.
CONCLUSION: Infusion of immunoglobulin can restore activity of BTH1677 in individuals with low serum ABA level. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  BTH1677; Imprime PGG; anti-beta glucan antibody; immunoglobulin; immunotherapy

Year:  2020        PMID: 32132045     DOI: 10.21873/anticanres.14090

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

Review 1.  Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review.

Authors:  Valeria Cognigni; Nicoletta Ranallo; Francesca Tronconi; Francesca Morgese; Rossana Berardi
Journal:  Explor Target Antitumor Ther       Date:  2021-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.